

Personal Data

Title	Prof. Dr. med.
First name	Michael
Last name	Platten
Current position	W3 professor (tenured full professor), Clinical director Department of Neurology and Division head Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology
Current institution, country	Department of Neurology, Medical Faculty Mannheim of Heidelberg University, University Medicine Mannheim (UMM), Mannheim, Germany and CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
ORCID	0000-0002-4746-887X

Qualifications and Career

Stages	Periods and Details
Degree	1991–1998 Medical School, University of Bonn, Germany; Medical School, University of London, UK; Harvard Medical School in Boston, US
Doctorate	1998 MD, Department of Neuropathology, University of Bonn, Germany; Supervisor: Prof. Dr. Andreas von Deimling
Stages of academic/professional career	2016– Professor (W3) of Neurology, Heidelberg University and Chairman, Department of Neurology, UMM, Germany 2013– Division Head CCU Neuroimmunology and Brain Tumor Immunology, DKFZ, Germany 2010– PI of several multicenter academically funded phase1 clinical trials, UKHD, UMM, DKFZ, Germany 2010–2015 Associate Professor (W3) of Experimental Neuroimmunology, Heidelberg University, Germany 2007–2013 Helmholtz Young Investigator Group Leader Experimental Neuroimmunology, DKFZ, Germany 2007–2016 Vice chair and senior attending, Department of Neurooncology (Department of Neurology 2014-2016), Heidelberg University, Germany 2006–2007 Attending (Neurology), University of Tübingen, Germany 2006 Habilitation in Neurology, University of Tübingen, Germany 2002–2004 Postdoctoral Fellow, Stanford University, USA 1999–2006 Residency (Neurology), University of Tübingen, Germany

Activities in the Research System**Institutional/Coordinating Responsibilities, Committee involvement**

2025–	Co-Coordinator, Cluster of Excellence SynthImmune (Engineering Immune Function with Synthetic Biology)
2025–	Ambassador for the European Research Council (ERC)
2024–	President, European Association for Neuro-Oncology (EANO)
2022–	Founder of Tcelltech, DKFZ spin-off company, Germany

- 2021– Internal Advisory Board, Health + Life Sciences Alliances Heidelberg Mannheim, Germany
- 2020– Vice Chair Neuro-Oncology Working Group (NOA), German Cancer Society
- 2019– Director, Mannheim Center for Translational Neuroscience, UMM, Germany
- 2019– Coordinator, Research Topic Immunology and Cancer, DKFZ, Germany
- 2018– Management Board Helmholtz-Institute of Translational Oncology (HI-TRON)
- 2018– Deputy Speaker CRC1389 (DFG-funded)

Scientific Meetings

- 2025 Organizing committee, UNITE Conference on Glioblastoma, Heidelberg Germany
- 2024 Past-Chair, EANO Scientific Committee, EANO conference - Glasgow, UK
- 2024 Organizer, New Frontiers in Immunology, Infection and Cancer Symposium - Heidelberg, Germany
- 2024 Organizing committee, Life-inspired Engineering Molecular Systems Conference, Heidelberg, Germany
- 2021 Chair, EANO Scientific Committee, EANO conference - virtual
- 2019 Chair, 21st annual NOA meeting - Mannheim, Germany
- 2019 Chair, EANO Scientific Committee, EANO conference - Lyon, France
- 2021 Chair, EANO Scientific Committee, EANO conference - virtual
- 2019 Chair, 21st annual NOA meeting - Mannheim, Germany

Ongoing Teaching and Mentoring Activities

- 2016– Lecturer Neurology, Heidelberg University, Germany
- 2011– Lecturer Neurooncology, Heidelberg University and DKFZ Heidelberg, Germany
- 2007– Lecturer Neuroimmunology, Heidelberg University and DKFZ Heidelberg, Germany

Reviewing Activities

Regular ad hoc referee of > 30 scientific journals, including Nature, Science, Cell and > 10 funding agencies including German Science Foundation, ERC. Editorial board in 7 scientific journals including Neuro-Oncology

Memberships in Scientific Societies (selected)

American Academy of Neurology, German Neurological Association, German Cancer Society, European Association of Neuro-Oncology (President), Society for Neuro-Oncology, Association for Cancer Immunotherapy, Society for Immunotherapy of Cancer, European Association of Tumor Immunotherapy, German Cancer Consortium

Supervision of Researchers in Early Career Phases

- 2006– Supervision of 20 PhD students, 23 MD students, 21 postdoctoral or physician scientists (incl. 4 Hertie Fellow Clinician Scientists: K. Sahm, L. Bunse, S. Räuber, K. Sanghvi), 1 junior group leader (Heidelberg University and DKFZ)

Scientific Results

Category A (*all: project design and supervision, * co-corresponding*)

1. Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, **Platten M**. IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. *Nat Cancer* 2026. DOI: 10.1038/s43018-026-01199-y. *Open access*
IDH1 vaccine shows promising 8-year outcomes in IDH-mutant astrocytomas

2. Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, **Platten M***, Green EW*. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy. *Nat Biotechnol* 2025; DOI: 10.1038/s41587-024-02161-y. *Open access*
Using artificial intelligence and single-cell sequencing to accelerate tumor-reactive T cell identification for personalized cancer immunotherapy.
3. Grassl N, Poschke I, Lindner K, Bunse L, Mildenerberger I, Boschert T, Jähne K, Green EW, Hülsmeier I, Jünger S, Kessler T, Suwala A, Sahm F, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Bendszus M, von Deimling A, Winkler F, Wick W, **Platten M***, Sahm K*. A H3K27M-targeted vaccine in adults with diffuse midline glioma. *Nat Med* 2023. DOI: 10.1038/s41591-023-02555-6. *Open access*
Mutation-specific peptide vaccine against midline gliomas used in patients for the first time.
4. Kilian M, Sheinin R, Tan CL, Krämer C, Friedrich M, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins R, Etminan N, von Deimling A, Wick W, Madi A*, Bunse L*, **Platten M***. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. *Cancer Cell* 2023. DOI: 10.1016/j.ccell.2022.12.007. *Open access*
Functionality of tumor-infiltrating cytotoxic T cells depends on the activation of T helper cells.
5. **Platten M**, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W (2021). A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature* 2021. DOI: 10.1038/s41586-021-03363-z. *Open access*
Main experimentalist and writing. Vaccination against mutated protein tested in brain tumor patients for the first time.
6. Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Gegner HM, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana FJ, von Deimling A, Wick W, Prinz M*, **Platten M***. Tryptophan metabolism drives dynamic immuno-suppressive myeloid states in IDH-mutant gliomas. *Nat Cancer* 2021. DOI: 10.1038/s43018-021-00201-z. *Open access*
Reactivation of paralyzed immune cells against brain tumors.
7. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, **Platten M**. Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. *Nat Med* 2018. DOI: 10.1038/s41591-018-0095-6.
Mutation in brain cancer cells stifles immune response.
8. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, **Platten M**. A vaccine targeting mutant IDH1 induces antitumour immunity. *Nature* 2014. DOI: 10.1038/nature13387.
First positive results toward a therapeutic brain cancer vaccine.
9. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritzschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I,

von Deimling A, Wick W, **Platten M**. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. *Nature* 2011. DOI: 10.1038/nature10491.

Chemical messenger makes brain tumors more aggressive.

10. **Platten M**, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. *Science* 2005. DOI: 10.1126/science.1117634.

Experimentalist and writing. Importance of amino acid tryptophan in regulating T cell immunity.

Category B

PATENTS AND CLINICAL DEVELOPMENTS (selected) *denotes leadership

1. **Platten M**, Schumacher T, Wick W. Peptides for use in treating or diagnosing IDH1R132H positive cancers (EP2800580B1, 2013); <https://patents.google.com/patent/EP2800580B1/en>
Conceived and led the development of mutant IDH1R132H-targeting peptide immunotherapies and diagnostics, resulting in a patent covering this therapeutic concept.
2. **Platten M**, Wick W, Bunse L, Bunse T, Sahm F. Method for the detection of antigen presentation (US20170254803A1, 2017); <https://patents.google.com/patent/US20170254803A1/en>
Co-developed and patented a method for detecting antigen presentation, enabling improved identification and validation of clinically relevant tumor antigens.
3. Clinical Trial 'Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)' (ClinicalTrials.gov ID: NCT02454634*)
Initiated and led the first-in-human Phase I clinical trial evaluating an IDH1R132H-specific peptide vaccine in patients with mutant IDH1 glioma.
4. Clinical Trial 'AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC)' (ClinicalTrials.gov ID: NCT03893903*)
Conceived and led a multicenter clinical trial investigating neoepitope-targeted vaccination strategies to enhance anti-tumor immune responses in diffuse glioma.
5. **Platten M**, Bunse T, Wick W, Ochs K, Ott M, Bunse L. Histone anti-cancer vaccines (WO2017009349A1, 2017); <https://patents.google.com/patent/WO2017009349A1/en>
Conceived and co-developed a novel cancer vaccination strategy targeting mutant histone epitopes, resulting in a patent for histone-directed immunotherapy approaches.
6. Clinical Trial 'A MulticENTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3)' (ClinicalTrials.gov ID: NCT04808245*)
Initiated and led a multicenter Phase I clinical trial evaluating a peptide vaccine targeting H3-mutated gliomas.

Academic Distinctions

2026	ERC PoC Grant (AI-TreatCancer)
2024	Falling Walls Science Breakthrough of the Year: Life Sciences
2024	ERC Advanced Grant (CENTRIC-BRAIN)
2024	Paul Martini Prize by the Paul Martini Foundation
2020	Fellow of the European Association of Neurology
2019–2020, 2022–2025	Global Highly Cited Researcher, cross topic, Clarivate Analytics
2019	German Cancer Award by the German Cancer Society
2012	Sir Hans Krebs Award
2011	Chica and Heinz Schaller Award
2010	Heinrich Pette Award by the German Society of Neurology
2002	Emmy Noether Fellow by the German Research Foundation